Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate

European Journal of Pharmacology

Volumn 667, Issue 1-3, 2011, Pages 153-159

  Angulo, Javier ^a   Peiró, Concepción ^b   Romacho, Tania ^b   Fernández, Argentina ^a   Cuevas, Begoña ^a   González Corrochano, Rocío ^c   Giménez Gallego, Guillermo ^c   De Tejada, Iñigo Sáenz ^a   Sánchez Ferrer, Carlos F ^b   Cuevas, Pedro ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Akt; Angiogenesis; Dobesilate; Endothelium; FGF; Proliferation; Vascular permeability; VEGF

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; ACETYLCHOLINE; FIBROBLAST GROWTH FACTOR; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ANIMALS; AORTA; CALCIUM DOBESILATE; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 80052023862     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.06.015     Document Type: Article

References (57)

1. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, J.E. Park, H.V. Nguyen, L.M. Aiello, N. Ferrara, and G.L. King Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N. Engl. J. Med. 331 1994 1480 1487 (Pubitemid 24356306)
2. H. Allain, A.A. Ramelet, E. Polard, and D. Bentue-Ferrer Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids Drug Saf. 27 2004 649 660 (Pubitemid 38980450)
3. J. Angulo, C.F. Sanchez-Ferrer, C. Peiro, J. Marin, and L. Rodriguez-Mañas Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved Hypertension 28 1996 583 592 (Pubitemid 26327953)
4. S. Ashikari-Hada, H. Habuchi, Y. Kariya, and K. Kimata Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins J. Biol. Chem. 280 2005 31508 31515 (Pubitemid 41291893)
5. D.O. Bates, N.J. Hillman, B. Williams, C.R. Neal, and T.M. Pocock Regulation of microvascular permeability by vascular endothelial growth factors J. Anat. 200 2002 581 597 (Pubitemid 34823050)
6. P. Berthet, J.C. Farine, and J.P. Barras Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy Int. J. Clin. Pract. 53 1999 631 636 (Pubitemid 30018938)
7. I.A. Bhutto, D.S. McLeod, T. Hasegawa, S.Y. Kim, C. Merges, P. Tong, and G.A. Lutty Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration Exp. Eye Res. 82 2006 99 110 (Pubitemid 43063401)
8. D.R. Bielenberg, C.A. Pettaway, S. Takashima, and M. Klagsbrun Neuropilins in neoplasms: expression, regulation, and function Exp. Cell Res. 312 2006 584 593 (Pubitemid 43290335)
9. J. Brunet, J.C. Farine, R.P. Garay, and P. Hannaert Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat Eur. J. Pharmacol. 358 1998 213 220 (Pubitemid 28498181)
10. A.M. Byrne, D.J. Bouchier-Hayes, and J.H. Harmey Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J. Cell. Mol. Med. 9 2005 777 794 (Pubitemid 43116546)
11. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
12. G. Conn, M.L. Bayne, D.D. Soderman, P.W. Kwok, K.A. Sullivan, T.M. Palisi, D.A. Hope, and K.A. Thomas Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor Proc. Natl. Acad. Sci. U. S. A. 87 1990 2628 2632
13. M.J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-Welsh VEGF-receptor signal transduction Trends Biochem. Sci. 28 2003 488 494 (Pubitemid 38340413)
14. P. Cuevas, and J.M. Arrazola Dobesilate in the treatment of plaque psoriasis Eur. J. Med. Res. 10 2005 373 376 (Pubitemid 41358533)
15. P. Cuevas, and J.M. Arrazola Therapeutic response of rosacea to dobesilate Eur. J. Med. Res. 10 2005 454 456 (Pubitemid 41614706)
16. P. Cuevas, D. Diaz-Gonzalez, G. Gimenez-Gallego, and M. Dujovny Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells Neurol. Res. 27 2005 797 800 (Pubitemid 41790263)
17. P. Cuevas, D. Diaz-Gonzalez, C. Garcia-Martin-Cordova, I. Sanchez, R.M. Lozano, G. Gimenez-Gallego, and M. Dujovny Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cells J. Cell. Mol. Med. 10 2006 225 230 (Pubitemid 44874304)
18. P. Cuevas, D. Diaz-Gonzalez, I. Sanchez, R.M. Lozano, G. Gimenez-Gallego, and M. Dujovny Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells Neurol. Res. 28 2006 127 130
19. P. Cuevas, F. Carceller, J. Angulo, R. Gonzalez-Corrochano, A. Cuevas-Bourdier, and G. Gimenez-Gallego Antiglioma effects of a new low molecular mass, inhibitor of fibroblast growth factor Neurosci. Lett. 491 2011 1 7
20. M. Detmar, L.F. Brown, K.P. Claffey, K.T. Yeo, O. Kocher, R.W. Jackman, B. Berse, and H.F. Dvorak Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis J. Exp. Med. 180 1994 1141 1146 (Pubitemid 24256627)
21. I.S. Fernandez, P. Cuevas, J. Angulo, P. Lopez-Navajas, A. Canales-Mayordomo, R. Gonzalez-Corrochano, R.M. Lozano, S. Valverde, J. Jimenez-Barbero, A. Romero, and G. Gimenez-Gallego Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors J. Biol. Chem. 285 2010 11714 11729
22. C. Fernandez-Tornero, R.M. Lozano, M. Redondo-Horcajo, A.M. Gomez, J.C. Lopez, E. Quesada, C. Uriel, S. Valverde, P. Cuevas, A. Romero, and G. Gimenez-Gallego Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate J. Biol. Chem. 278 2003 21774 21781 (Pubitemid 36792581)
23. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676 (Pubitemid 36749215)
24. J.A. Foekens, H.A. Peters, N. Grebenchtchikov, M.P. Look, M.E. Meijer-van Gelder, A. Geurts-Moespot, T.H. van der Kwast, C.G. Sweep, and J.G. Klijn High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res. 61 2001 5407 5414 (Pubitemid 32694919)
25. J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N. Engl. J. Med. 333 1995 1757 1763
26. G. Gimenez-Gallego, G. Conn, V.B. Hatcher, and K.A. Thomas Human brain-derived acidic and basic fibroblast growth factors: amino terminal sequences and specific mitogenic activities Biochem. Biophys. Res. Commun. 135 1986 541 548 (Pubitemid 16049445)
27. H. Gitay-Goren, S. Soker, I. Vlodavsky, and G. Neufeld The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules J. Biol. Chem. 267 1992 6093 6098
28. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
29. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, D.M. Jablons, C.J. Langer, R.F. DeVore III, J. Gaudreault, L.A. Damico, E. Holmgren, and F. Kabbinavar Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J. Clin. Oncol. 22 2004 2184 2191 (Pubitemid 41095154)
30. A.J. Karayiannakis, K.N. Syrigos, A. Polychronidis, A. Zbar, G. Kouraklis, C. Simopoulos, and G. Karatzas Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery Ann. Surg. 236 2002 37 42 (Pubitemid 34686448)
31. S. Kliche, and J. Waltenberger VEGF receptor signaling and endothelial function IUBMB Life 52 2001 61 66 (Pubitemid 33769671)
32. M. Korc, and R.E. Friesel The role of fibroblast growth factors in tumor growth Curr. Cancer Drug Targets 9 2009 639 651
33. S. Lameynardie, C. Chiavaroli, P. Travo, R.P. Garay, and N. Pares-Herbute Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats Eur. J. Pharmacol. 510 2005 149 156 (Pubitemid 40312401)
34. S.S. Lee, Y.S. Joo, W.U. Kim, D.J. Min, J.K. Min, S.H. Park, C.S. Cho, and H.Y. Kim Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis Clin. Exp. Rheumatol. 19 2001 321 324
35. J.H. Lee, M.D. Canny, A. De Erkenez, D. Krilleke, Y.S. Ng, D.T. Shima, A. Pardi, and F. Jucker A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165 Proc. Natl. Acad. Sci. U. S. A. 102 2005 18902 18907 (Pubitemid 43049539)
36. E.B. Leite, M.C. Mota, J.R. de Abreu, and J.G. Cunha-Vaz Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy Int. Ophthalmol. 14 1990 81 88 (Pubitemid 20197614)
37. B. Li, A.K. Ogasawara, R. Yang, W. Wei, G.W. He, T.F. Zioncheck, S. Bunting, A.M. de Vos, and H. Jin KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF Hypertension 39 2002 1095 1100 (Pubitemid 34620130)
38. M.H. Liu, H.K. Jin, H.S. Floten, Q. Yang, A.P. Yim, A. Furnary, T.F. Zioncheck, S. Bunting, and G.W. He Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats J. Pharmacol. Exp. Ther. 296 2001 473 477 (Pubitemid 32112475)
39. M.H. Liu, H. Jin, H.S. Floten, Z. Ren, A.P. Yim, and G.W. He Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery Ann. Thorac. Surg. 73 2002 819 824 (Pubitemid 34188321)
40. S.S. Lynch, and C.M. Cheng Bevacizumab for neovascular ocular diseases Ann. Pharmacother. 41 2007 614 625 (Pubitemid 46625484)
41. A.A. Miles, and E.M. Miles Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs J. Physiol. 118 1952 228 257
42. C. Peiro, J. Angulo, J. Regadera, J.L. Llergo, A. Sanchez-Ferrer, L. Rodriguez-Mañas, and C.F. Sanchez-Ferrer Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren-2 transgenic rats Eur. J. Pharmacol. 324 1997 257 265 (Pubitemid 27174615)
43. C. Peiro, S. Vallejo, F. Gembardt, V. Azcutia, S. Heringer-Walther, L. Rodriguez-Mañas, H.P. Schultheiss, C.F. Sanchez-Ferrer, and T. Walther Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function J. Hypertens. 25 2007 2421 2425 (Pubitemid 350060381)
44. A. Pineda-Lucena, M.A. Jimenez, J.L. Nieto, J. Santoro, M. Rico, and G. Gimenez-Gallego 1H-NMR assignment and solution structure of human acidic fibroblast growth factor activated by inositol hexasulfate J. Mol. Biol. 242 1994 81 98
45. M.L. Ribeiro, A.I. Seres, A.M. Carneiro, M. Stur, A. Zourdani, P. Caillon, and J.G. Cunha-Vaz Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study Graefes Arch. Clin. Exp. Ophthalmol. 244 2006 1591 1600 (Pubitemid 44830817)
46. R. Rota, C. Chiavaroli, R.P. Garay, and P. Hannaert Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats Eur. J. Pharmacol. 495 2004 217 224 (Pubitemid 38891879)
47. T. Shih, and C. Lindley Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin. Ther. 28 2006 1779 1802 (Pubitemid 46038527)
48. J.R. Smith, V.B. Lanier, R.M. Braziel, K.M. Falkenhagen, C. White, and J.T. Rosenbaum Expression of vascular endothelial growth factor and its receptors in rosacea Br. J. Ophthalmol. 91 2007 226 229 (Pubitemid 46202875)
49. A. Starzec, R. Vassy, A. Martin, M. Lecouvey, M. Di Benedetto, M. Crepin, and G.Y. Perret Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1 Life Sci. 79 2006 2370 2381 (Pubitemid 44772930)
50. C.A. Stein Suramin: a novel antineoplastic agent with multiple potential mechanisms of action Cancer Res. 53 1993 2239 2248 (Pubitemid 23156807)
51. G. Tolstanova, T. Khomenko, X. Deng, L. Chen, A. Tarnawski, A. Ahluwalia, S. Szabo, and Z. Sandor Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF J. Pharmacol. Exp. Ther. 328 2009 749 757
52. C.W. Vander Kooi, M.A. Jusino, B. Perman, D.B. Neau, H.D. Bellamy, and D.J. Leahy Structural basis for ligand and heparin binding to neuropilin B domains Proc. Natl. Acad. Sci. U. S. A. 104 2007 6152 6157 (Pubitemid 47186064)
53. C. Vogel, A. Bauer, M. Wiesnet, K.T. Preissner, W. Schaper, H.H. Marti, and S. Fischer Flt-1 but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway J. Cell. Physiol. 212 2007 236 243 (Pubitemid 46867606)
54. W. Wei, Z.W. Chen, Q. Yang, H. Jin, A. Furnary, X.Q. Yao, A.P. Yim, and G.W. He Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery Vascul. Pharmacol. 46 2007 253 259 (Pubitemid 46124089)
55. 164-driven angiogenesis, in part by blocking S6Kinase Arterioscler. Thromb. Vasc. Biol. 29 2009 1172 1178
56. I. Zachary, and G. Gliki Signaling transduction mechanisms mediating biological actions of vascular endothelial growth factor Cardiovasc. Res. 49 2001 568 581 (Pubitemid 32146420)
57. W. Zhang, R. Swanson, Y. Xiong, B. Richard, and S.T. Olson Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains J. Biol. Chem. 281 2006 37302 37310 (Pubitemid 46042034)